These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37682449)

  • 1. The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?
    Koufakis T; Zografou I; Doumas M; Kotsa K
    Am J Cardiovasc Drugs; 2023 Nov; 23(6):601-608. PubMed ID: 37682449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
    Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
    Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.
    Zhou JB; Bai L; Wang Y; Yang JK
    Int J Clin Pract; 2016 Feb; 70(2):132-41. PubMed ID: 26709610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
    Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
    JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.
    Loh HH; Yee A; Loh HS; Sukor N; Kamaruddin NA
    Prim Care Diabetes; 2016 Jun; 10(3):210-9. PubMed ID: 26392074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome.
    Panda SP
    Endocr Metab Immune Disord Drug Targets; 2023; 23(2):179-187. PubMed ID: 35642117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
    Deacon CF
    Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
    Gamble JM; Donnan JR; Chibrikov E; Twells LK; Midodzi WK; Majumdar SR
    Sci Rep; 2018 Oct; 8(1):15142. PubMed ID: 30310100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
    Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
    Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
    Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
    Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
    Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
    Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Contra].
    Müller UA
    Dtsch Med Wochenschr; 2011 Mar; 136(11):547. PubMed ID: 21351042
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
    Yang CT; Lin WH; Li LJ; Ou HT; Kuo S
    Clin Pharmacol Ther; 2021 Aug; 110(2):464-472. PubMed ID: 33866549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
    Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
    Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis.
    Mishriky BM; Cummings DM; Tanenberg RJ
    Diabetes Res Clin Pract; 2015 Aug; 109(2):378-88. PubMed ID: 26059071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.